147 related articles for article (PubMed ID: 31169023)
1. Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study.
Virgili G; Parravano M; Viola F; Varano M
Eur J Ophthalmol; 2020 Sep; 30(5):1069-1075. PubMed ID: 31169023
[TBL] [Abstract][Full Text] [Related]
2. OLIMPIC: a 12-month study on the criteria driving retreatment with ranibizumab in patients with visual impairment due to myopic choroidal neovascularization.
Ricci F; Staurenghi G; Varano M; Eandi C; Sinibaldi TL; Colombo L; Bartezaghi M; Bassanini S
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):759-768. PubMed ID: 30680452
[TBL] [Abstract][Full Text] [Related]
3. VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.
Ceklic L; Munk MR; Wolf-Schnurrbusch U; Gekkieva M; Wolf S
Retina; 2017 Apr; 37(4):687-693. PubMed ID: 27533774
[TBL] [Abstract][Full Text] [Related]
4. Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study.
Amoaku WM; Gale RP; Lotery AJ; Menon G; Sivaprasad S; Petrillo J; Quinn J
PLoS One; 2015; 10(6):e0128403. PubMed ID: 26039355
[TBL] [Abstract][Full Text] [Related]
5. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Wu TT; Kung YH
Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
7. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
8. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
9. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
11. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of antiangiogenic treatment results in choroidal neovascularization related to pathological myopia].
Carvalho B; Freitas-Costa P; Pinheiro-Costa J; Falcão M; Carneiro Â; Falcão-Reis F
Acta Med Port; 2014; 27(1):49-58. PubMed ID: 24581193
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
16. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
Silva RM; Ruiz-Moreno JM; Rosa P; Carneiro A; Nascimento J; Rito LF; Cachulo ML; Carvalheira F; Murta JN
Retina; 2010 Mar; 30(3):407-12. PubMed ID: 20094007
[TBL] [Abstract][Full Text] [Related]
18. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
Sekfali R; Mimoun G; Cohen SY; Querques G; Bandello F; Sacconi R; Souied EH; Capuano V
Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
[TBL] [Abstract][Full Text] [Related]
19. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M
Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
